linjc16/ctgov huggingface dataset:
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.

Official Title
-----------------
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Conditions
-----------------
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer

Intervention / Treatment
-----------------
* Radiation: Standard Trimodality Breast Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned A biopsy clip placed at the time of diagnostic biopsy 18 years of age or older Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint - this is justified as there is no individual benefit to study participation Able to provide written consent prior to any research related activities Exclusion Criteria: Stage IV breast cancer T4 breast cancer Previous ipsilateral breast cancer Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast biopsy between chemotherapy and surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete Pathologic Response (pCR) | The primary aim of this feasibility study is to determine whether breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC) can accurately predict complete pathologic response (pCR) in women with biopsyproven triple negative or HER2+ breast cancer. | 6 Months Post Surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications and Side Effects of the Needle Biopsy Procedure after NAC | Incidence of Adverse Events | 6 Months Post Surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer
Recurrent AA Amyloidosis After Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

Detailed Description
-----------------
AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.

Official Title
-----------------
Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival

Conditions
-----------------
AA Amyloidosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal transplantation recipients whose primary renal disease is AA amyloidosis; patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1) Renal transplantation recipients whose primary diseases are other than AA amyloidosis (for control group 2) Exclusion Criteria: Patients who are unwilling or unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Recurrent AA amyloidosis<br>Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft | |
| Control group 1<br>Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft | |
| Control group 2<br>Renal transplant recipients whose primary diseases are other than amyloidosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Allograft survival |  | 1 - 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Allograft rejection |  | 1 - 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
amyloidosis, renal transplantation
Atrial Fibrillation Ablation: Radiofrequency or Cryoablation?

Study Overview
=================
Brief Summary
-----------------
The study aims to compare 3 techniques routinely used for paroxysmal atrial fibrillation ablation: radiofrequency catheter ablation without contact-force, radiofrequency catheter ablation with contact-force and cryoablation. The hypothesis is the non-inferiority between the 3 techniques in terms of free-from atrial fibrillation survival (primary criteria). It will also compare lenght of procedure, radioscopy time and immediate complications (secondary criteria).

Official Title
-----------------
A Comparison of Radiofrequency Catheter Ablation With or Without Contact-force and Cryoablation for Paroxysmal Atrial Fibrillation Ablation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had an atrial fibrillation for symptomatic paroxysmal atrial fibrillation, refractory to antiarrhythmic drugs, between 01/01/2014 and 30/09/2017 in CHR Metz-Thionville Exclusion Criteria: Patients not willing to participate via using their medical files
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Atrial Fibrillation survival | Free from atrial fibrillation survival | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immediate complications | The number of immediate complications encountered | Day 1 | 
| Radioscopy duration | Radioscopy duration | Day 1 | 
| Lenght of procedure | Overall duration of the procedure | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, Catheter ablation, Radiofrequency, Contact-force, Cryoablation
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)

Study Overview
=================
Brief Summary
-----------------
The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.

Official Title
-----------------
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone

Conditions
-----------------
Severe Dengue

Intervention / Treatment
-----------------
* Drug: Dexamethasone
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test) And still in febrile phase (Body temp>37.5 C) Shock : Sys<90mmHg or Narrow PP (<20mmHg) orTachycardia (pulse>100/min) with Hematocrit decreased ≥20 % Fluid accumulation and respiratory distress Severe bleeding Severe organ involvement Exclusion Criteria: Severe dengue> 24 hrs Dengue without warning signs Pregnancy Patient who receieved any steroid within 1 week

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Patients treated with placebo<br>|
| Experimental: Intervention<br> | Drug: Dexamethasone<br>* Patients treated with dexamethasone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | The use of steroids in dengue will reduce mortality in rate | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay | The use of steroids in dengue will reduce Length of hospital stay in day | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Steroid, Severe Dengue, Dexamethasone
Left Ventricular Function and Remodelling During Permanent Pacing

Study Overview
=================
Brief Summary
-----------------
Background - Pacemaker treatment gives asynchronous activation of the heart that often results in decreased heart function and clinical heart failure. New pacemaker types that stimulates both left and right ventricle ( biventricular pacemakers ) is introduced to the treatment of patients with heart failure, decreased left ventricular function and ECG signs with left bundle branch block. Hypothesis - Ventricular pacing results in remodelling of the left ventricle and decreased left ventricular function. Biventricular pacing do not do this. Ventricular pacing results in heart failure and increased wall stress with decreased 6 minutes walk test and increased BNP in blood samples. This is not seen by biventricular pacing. Materials and methods - 3 studies. All patients are examined by echocardiography 2-dimensional, M-mode, 3-dimensional and with tissue harmonic imaging. Study 1) Patients with AV-conduction disorder that needs pacemaker treatment are randomized to DDD-pacemaker or biventricular pacemaker. Study 2) Patients with sick sinus syndrome included in DANPACE are randomized to AAI- or DDD-pacemaker. Study 3 ) Acute study to examine the changes in patients AV-block before DDD-pacemaker implantation and after implantation.

Official Title
-----------------
Left Ventricular Function and Remodelling During Permanent Pacing

Conditions
-----------------
Sick Sinus Syndrome, AV-Block

Intervention / Treatment
-----------------
* Device: AAI vs. DDD vs. BIV pacing in different patients groups


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sick sinus syndrome AV-block Exclusion Criteria: Atrial fibrillation AMI Heart valve disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: AAI vs. DDD vs. BIV pacing in different patients groups|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-dimensional left ventricular ejection fraction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TDI echo parameters |  |  | 
| 6 MHW |  |  | 
| NT-proBNP |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sick sinus syndrome, AV-block
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis

Study Overview
=================
Brief Summary
-----------------
Endophthalmitis is a severe inflammatory eye condition with profound impairment of vision, which can lead to irreversible visual loss and requires immediate treatment. There is no way to completely prevent endophthalmitis, however, through prophylactic methods, it is possible to reduce its incidence. Currently, the only technique that has reached category II of evidence in reducing the risks of endophthalmitis is the use of 5% povidone-iodine eye drops, moments before surgery. In 2007, the European Society of Cataract and Refractive Surgery (ESCRS) released a large multicenter randomized clinical trial, with data on the reduction in the rates of endophthalmitis, using the intracameral antibiotic therapy technique of perioperative cefuroxime. However, much is discussed about the risks related to the technique, such as dilutional errors, contamination, anaphylaxis and cost-effectiveness, which still makes the conduct debatable. The study evaluates the use of intracameral Moxifloxacin 0.5% (Vigamox®) as prophylaxis in cases of endophthalmitis after open ocular trauma;

Official Title
-----------------
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis

Conditions
-----------------
Endophthalmitis, Trauma, Corneal

Intervention / Treatment
-----------------
* Drug: Intraocular Instillation Solution
* Drug: Moxifloxacin Ophthalmic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: open globe trauma Exclusion Criteria: endophthalmitis at the beginning

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: INTRACAMERAL MOXIFLOXACIN<br>After the surgery, the antibiotic is intracameral administered, Moxifloxacin 0.5% 0.1mL. | Drug: Intraocular Instillation Solution<br>* Intracameral Moxifloxacin 0.5%<br>* Other names: Intracameral;|
| Active Comparator: TOPICAL MOXIFLOXACIN<br>After the surgery, the antibiotic is topical administered, Moxifloxacin 0.5% 0.1mL. | Drug: Moxifloxacin Ophthalmic<br>* Topical Moxifloxacin 0.5%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endophthalmitis | Evaluate the incidence of Endophthalmitis | 90 days |
Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
In this randomized controlled clinical trial, we compare the effects of timolol versus placebo for treatment of myopic regression after LASIK

Official Title
-----------------
Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After Laser in Situ Keratomileusis: A Randomized Clinical Trial

Conditions
-----------------
Myopic Regression

Intervention / Treatment
-----------------
* Drug: Timolol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with myopic regression equal or more than 0.5 D with minimum age of 20 years, cylinder ≤ -1.00 D, corrected distance visual acuity (CDVA) of at least 20/40 were included. Exclusion Criteria: Patients with a history of previous ocular surgery, keratoconus or any ectatic corneal disorder, keratoconus suspect by topography, preoperative corneal opacity, any corneal dystrophies, presence of pterygium, retinal disorders, collagen vascular disorders, diabetes mellitus, glaucoma, cataract, pregnancy, breast feeding systemic corticosteroid therapy were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br>included patients who received artificial tear twice a day as control group. | Drug: Placebo<br>* artificial tear twice a day<br>|
| Experimental: Timolol group<br>included the patients with myopic regression who received timolol 0.5% eye drop twice a day | Drug: Timolol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spherical Equivalent | Effect of timolol use in timolol group will be compared with placebo group at month 6. Moreover, the changes of intragroup spherical equivalent will be assessed in both group 6 months after timolol application. | spherical equivalent at month 6 |
Choroidal Changes Post Short Term Exposure To Virtual Reality Devices

Study Overview
=================
Brief Summary
-----------------
This is a prospective, randomized, controlled, contralateral eye, clinical study. The objective of the study is to determine the impact of Virtual Reality (VR) usage on choroidal thickness when viewed through a test display compared to a control (standard) VR display. The hypothesis is that there will be less choroidal thinning in the eye viewing the test VR screen compared to the eye viewing the control VR screen.

Official Title
-----------------
Choroidal Changes Post Short Term Exposure To Virtual Reality Devices

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Visu


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Is at least 13 years of age and has full legal capacity to volunteer; Has read and signed an information consent letter; Visual Acuity of +0.20 logMAR or better in each eye; Is willing and able to follow instructions and maintain the appointment schedule. Key Exclusion Criteria: Is participating in any concurrent clinical or research study; Has any known active ocular disease and/or infection; Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; Is amblyopic in either eye; Has a colour vision abnormality; Commonly experiences motion sickness.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized, contralateral eye study
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Visu OD, Control OS<br>Contralateral eye study | Device: Visu<br>* An experimental (test) virtual reality display<br>|
| Other: Control OD, Visu OS<br>Contralateral eye study | Device: Visu<br>* An experimental (test) virtual reality display<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choroidal thickness |  | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choroidal thickness |  | 3 months | 
| Axial length |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Choroidal thickness, Virtual reality
Study of Myasthenic Crisis in China

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter, prospective, observational research. It will register the basic demographic information, medical history characteristics, clinical features, auxiliary examinations, treatment, outcomes of tracheal intubation/ventilator related events, and clinical outcomes of Myasthenic Crisis patients. The objectives including: Obtain epidemiological data of MC in China; Establish a standardized registration system for MC patients in China; Explore the epidemiology, clinical characteristics, serological characteristics, clinical characteristics of MC, predisposing and predictive factors, extubation process/time, weaning/extubation outcome and predictors of clinical outcome in Chinese MC patients.

Official Title
-----------------
A Multicenter Prospective Registration Study of Myasthenic Crisis in China

Conditions
-----------------
Myasthenia Gravis, Myasthenic Crisis

Intervention / Treatment
-----------------
* Other: no interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical history and signs of fluctuating weakness and fatigability; seropositivity forAChR/MuSKantibodies; If negative or the tested antibodies, positive repetitive nerve stimulation(RNS) at low frequency(2-5Hz) is required; Crisis: a serious, life-threatening, rapid worsening of MG requiring intubation or noninvasive ventilation to avoid intubation. Impending crisis: rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks) with blood gases suggest hypoxia (oxygen saturation <95%) or elevated carbon dioxide (paco2>50mmHg). Exclusion Criteria: the RNS had over 100% increase after high frequency stimulation or R2 repeats,to differentiate from lambert-Eaton syndrome and congenital MG. except when intubation or noninvasive ventilation are employed during routine postoperative management.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Myasthenic Crisis Cohort<br> | Other: no interventions<br>* no interventions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MG-ADL of 3 years after off-mechanical ventilation |  | Sep,2026 |